HALOZYME THERAPEUTICS, INC. Business Combination, Integration Related Costs
HALOZYME THERAPEUTICS, INC. (HALO) reported Business Combination, Integration Related Costs of $8.70 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-02-20.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationIntegrationRelatedCosts · last filed 2024-02-20
- HALOZYME THERAPEUTICS, INC. business combination, integration related costs for the quarter ending 2022-09-30 was $8.70M.
- HALOZYME THERAPEUTICS, INC. business combination, integration related costs for the quarter ending 2022-06-30 was $8.70M.
- HALOZYME THERAPEUTICS, INC. business combination, integration related costs for fiscal 2022 was $8.70M.
| Period end | Business Combination, Integration Related Costs 3 month | Business Combination, Integration Related Costs 6 month | Business Combination, Integration Related Costs 12 month |
|---|---|---|---|
| 2022-12-31 | $8.70M 10-K · filed 2024-02-20 | ||
| 2022-09-30 | $8.70M 10-Q · filed 2022-11-08 | $17.40M derived: sum of 2 quarters · filed 2022-11-08 | |
| 2022-06-30 | $8.70M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |